These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 35978666)

  • 1. Alteration in gut microbial characteristics of patients with acromegaly.
    Babayeva A; Ozkul C; Coskun M; Uzun A; Yalcin MM; Yalinay M; Akturk M; Toruner FB; Karakoc MA; Yetkin I; Altinova AE
    Endocrine; 2024 May; ():. PubMed ID: 38822184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presepsin as a biomarker of bacterial translocation and an indicator for the prescription of probiotics in cirrhosis.
    Efremova I; Maslennikov R; Poluektova E; Medvedev O; Kudryavtseva A; Krasnov G; Fedorova M; Romanikhin F; Zharkova M; Zolnikova O; Bagieva G; Ivashkin V
    World J Hepatol; 2024 May; 16(5):822-831. PubMed ID: 38818295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Causal effect between gut microbiota and pancreatic cancer: a two-sample Mendelian randomization study.
    Jiang Z; Mou Y; Wang H; Li L; Jin T; Wang H; Liu M; Jin W
    BMC Cancer; 2023 Nov; 23(1):1091. PubMed ID: 37950180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal Microbiome in Dogs with Chronic Hepatobiliary Disease: Can We Talk about the Gut-Liver Axis?
    Habermaass V; Olivero D; Gori E; Mariti C; Longhi E; Marchetti V
    Animals (Basel); 2023 Oct; 13(20):. PubMed ID: 37893898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota.
    Maslennikov R; Alieva A; Poluektova E; Zharikov Y; Suslov A; Letyagina Y; Vasileva E; Levshina A; Kozlov E; Ivashkin V
    World J Gastroenterol; 2023 Jul; 29(27):4236-4251. PubMed ID: 37545638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accounting Gut Microbiota as the Mediator of Beneficial Effects of Dietary (Poly)phenols on Skeletal Muscle in Aging.
    Ticinesi A; Nouvenne A; Cerundolo N; Parise A; Meschi T
    Nutrients; 2023 May; 15(10):. PubMed ID: 37242251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut Microbiome Characteristics in IgA Nephropathy: Qualitative and Quantitative Analysis from Observational Studies.
    Han S; Shang L; Lu Y; Wang Y
    Front Cell Infect Microbiol; 2022; 12():904401. PubMed ID: 35656030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut dysbiosis and body composition in cirrhosis.
    Maslennikov R; Ivashkin V; Alieva A; Poluektova E; Kudryavtseva A; Krasnov G; Zharkova M; Zharikov Y
    World J Hepatol; 2022 Jun; 14(6):1210-1225. PubMed ID: 35978666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis.
    Maslennikov R; Ivashkin V; Efremova I; Poluektova E; Kudryavtseva A; Krasnov G
    World J Gastroenterol; 2022 Mar; 28(10):1067-1077. PubMed ID: 35431497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut Microbiota and Biomarkers of Endothelial Dysfunction in Cirrhosis.
    Efremova I; Maslennikov R; Poluektova E; Medvedev O; Kudryavtseva A; Krasnov G; Fedorova M; Romanikhin F; Bakhitov V; Aliev S; Sedova N; Kuropatkina T; Ivanova A; Zharkova M; Pervushova E; Ivashkin V
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut Dysbiosis and Hemodynamic Changes as Links of the Pathogenesis of Complications of Cirrhosis.
    Efremova I; Maslennikov R; Poluektova E; Zharkova M; Kudryavtseva A; Krasnov G; Fedorova M; Shirokova E; Kozlov E; Levshina A; Ivashkin V
    Microorganisms; 2023 Aug; 11(9):. PubMed ID: 37764046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria.
    Hsu PI; Pan CY; Kao JY; Tsay FW; Peng NJ; Kao SS; Wang HM; Tsai TJ; Wu DC; Chen CL; Tsai KW;
    Helicobacter; 2018 Aug; 23(4):e12498. PubMed ID: 29897654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut dysbiosis is associated with poorer long-term prognosis in cirrhosis.
    Maslennikov R; Ivashkin V; Efremova I; Alieva A; Kashuh E; Tsvetaeva E; Poluektova E; Shirokova E; Ivashkin K
    World J Hepatol; 2021 May; 13(5):557-570. PubMed ID: 34131470
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.